Pacific Shuanglin Bio-pharmacy Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Xiankui Rong

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	1.1yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	1.1yrs

Recente managementupdates

Recent updates

CEO

Xiankui Rong (50 yo)

1.1yrs

Tenure

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Yehong Wang	CFO & Accounting Supervisor	3.7yrs	CN¥1.57m	0.012% CN¥ 1.9m
Lei Yan	Deputy GM & Director	less than a year	CN¥1.61m	geen gegevens
Wenbin Si	Deputy GM & Non-Independent Director	less than a year	CN¥101.00k	0.000030% CN¥ 5.0k
Xiaoying Huang	Deputy GM & Non-Independent Director	less than a year	CN¥101.00k	geen gegevens
Lan Ye	Deputy GM & Non-Independent Director	less than a year	CN¥101.00k	geen gegevens
Yulin Zhao	Board Secretary	5.5yrs	CN¥1.88m	0.022% CN¥ 3.7m
Xiankui Rong	General Manager	1.1yrs	geen gegevens	geen gegevens

0.9yrs

Gemiddelde duur

43yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 000403 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Lei Yan	Deputy GM & Director	less than a year	CN¥1.61m	geen gegevens
Wenbin Si	Deputy GM & Non-Independent Director	1.1yrs	CN¥101.00k	0.000030% CN¥ 5.0k
Xiaoying Huang	Deputy GM & Non-Independent Director	1.1yrs	CN¥101.00k	geen gegevens
Lan Ye	Deputy GM & Non-Independent Director	1.1yrs	CN¥101.00k	geen gegevens
Shaolan Fu	Co-Chairman	3.7yrs	CN¥3.05m	geen gegevens
Li Yang	Director	less than a year	CN¥1.92m	1.44% CN¥ 238.6m
Zuojun Dong	Independent Director	3.7yrs	CN¥100.00k	geen gegevens
Hao Li	Chairman	1.1yrs	geen gegevens	geen gegevens
Jun Yin	Independent Director	1.1yrs	CN¥18.60k	geen gegevens
Wenqi Wang	Independent Director	1.1yrs	CN¥18.60k	geen gegevens
Hui Guo	Chairman of the Supervisory Board	1.1yrs	geen gegevens	geen gegevens
Jun Liu	Independent Director	less than a year	CN¥6.00k	geen gegevens

1.1yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 000403 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.1 jaar), wat duidt op een nieuw bestuur.

Pacific Shuanglin Bio-pharmacy Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Pacific Shuanglin Bio-pharmacy Co., LTD, Annual General Meeting, May 21, 2024

Pacific Shuanglin Bio-pharmacy Co., LTD Approves Board Appointments

Pacific Shuanglin Bio-pharmacy Co., LTD, Annual General Meeting, May 22, 2023

Pacific Shuanglin Bio-pharmacy Co., LTD, Annual General Meeting, May 20, 2022

Recent updates

Pacific Shuanglin Bio-Pharmacy Co., Ltd Proposes Dividend for the First Half of 2024

Third quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.25 in 3Q 2023)

Investor sentiment improves as stock rises 24%

Pacific Shuanglin Bio-pharmacy Co., LTD to Report Q3, 2024 Results on Oct 28, 2024

Second quarter 2024 earnings released: EPS: CN¥0.28 (vs CN¥0.12 in 2Q 2023)

Pacific Shuanglin Bio-pharmacy Co., LTD to Report First Half, 2024 Results on Aug 28, 2024

Pacific Shuanglin Bio-pharmacy Co., LTD Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 28 June 2024

Pacific Shuanglin Bio-pharmacy Co., LTD, Annual General Meeting, May 21, 2024

First quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.077 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥0.84 (vs CN¥0.80 in FY 2022)

Pacific Shuanglin Bio-pharmacy Co., LTD to Report Q1, 2024 Results on Apr 27, 2024

Pacific Shuanglin Bio-pharmacy Co., LTD announced a financing transaction

Pacific Shuanglin Bio-pharmacy Co., LTD to Report Fiscal Year 2023 Results on Apr 27, 2024

Pacific Shuanglin Bio-pharmacy Co., LTD Approves Board Appointments

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.16 in 2Q 2022)

Pacific Shuanglin Bio-pharmacy Co., LTD Announces Final Dividend on A Shares for the Year 2022, Payable on July 20, 2023

Pacific Shuanglin Bio-Pharmacy Co., Ltd Approves 2022 Profit Distribution Plan

Pacific Shuanglin Bio-pharmacy Co., LTD, Annual General Meeting, May 22, 2023

First quarter 2023 earnings released: EPS: CN¥0.077 (vs CN¥0.14 in 1Q 2022)

Investor sentiment improves as stock rises 15%

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.17 in 3Q 2021)

Pacific Shuanglin Bio-pharmacy Co., LTD (SZSE:000403) commences an Equity Buyback Plan for CNY 80 million worth of its shares, under the authorization approved on July 20, 2022.

Second quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.16 in 2Q 2021)

Pacific Shuanglin Bio-Pharmacy Co., Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on July 15, 2022

Investor sentiment improved over the past week

Pacific Shuanglin Bio-Pharmacy Co., Ltd Approves Cash Dividend for the Year 2021

Pacific Shuanglin Bio-Pharmacy Co., Ltd Proposes Cash Dividend for 2021

Pacific Shuanglin Bio-pharmacy Co., LTD, Annual General Meeting, May 20, 2022

First quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.089 in 1Q 2021)

Full year 2021 earnings released: EPS: CN¥0.55 (vs CN¥0.38 in FY 2020)

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.083 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.077 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.38 (vs CN¥0.33 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.38 (vs CN¥0.33 in FY 2019)

Southern Shuanglin Bio-pharmacy Co., Ltd. to Report Fiscal Year 2020 Results on Apr 20, 2021

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd